Cost Curve
everything drug pricing and policy, every day
Connect
And a new paper underscores how tough it can be to talk about launch prices
Plus a bunch of items that I missed last week on everything from a row in the UK to pricing decisions in an increasingly competitive rare disease
And retail pharmacy is in deep trouble. Could a new effort from Optum reverse the trend?
Plus a new filing from pharma companies in the latest legal battle over the IRA
And is the government getting wobbly on its objections to the 340B rebate model?
And Dr. Oz had some worthwhile thoughts on PBMs and drug pricing last week
Plus details on the BU game, a link on the state of biotech in Boston, and a poll about what patients and clinicians think about health insurance
Plus a Cuban-vs-Arnold faceoff, a super-cheap biosimilar, and a little NCAA hockey talk
Plus a story about a 340B robot and a 340B analysis that is equal parts intriguing and useless
And copay accumulator bans continue to spread across the country ... but does it matter?
And I have a survey on what conferences you attend ... I’d be grateful for your input
It's a day of quick hits ... here's to a great weekend
